Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about NVAX, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Novavax COVID-19 Vaccine | COVID-19 | Phase 4 · NCT06065176 | Completed |
| Pfizer COVID-19 mRNA vaccine (2023-2024 formula… | COVID-19 | Phase 4 · NCT06065176 | Completed |
| Pfizer mRNA COVID-19 vaccine | COVID-19 | Phase 4 · NCT06633835 | Completed |
| protein subunit: Novavax COVID-19 vaccine | COVID-19 | Phase 4 · NCT06633835 | Completed |
| Aluminum Hydroxide Adjuvanted Inactivated… | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Phase 3 · NCT05249816 | Completed |
| Bivalent BA.4/5 | COVID-19 | Phase 2/3 · NCT05925127 | Completed |
| CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS… | COVID-19 | Phase 3 · NCT06291857 | Completed |
| coformulated CIC Vaccine | COVID-19 | Phase 2/3 · NCT06482359 | Withdrawn |
| Fluzone HD trivalent | COVID-19 | Phase 2/3 · NCT06482359 | Withdrawn |
| Trivalent Influenza Vaccine | COVID-19 | Phase 3 · NCT06291857 | Completed |
| Quadrivalent Inactivated Influenza Vaccine | Influenza, Human | Phase 3 · NCT04120194 | Completed |
| Formulation buffer | Respiratory Syncytial Virus Infections | Phase 3 · NCT02624947 | Completed |
| Licensed seasonal influenza vaccine | SARS-CoV-2 Infection | Phase 3 · NCT04583995 | Completed |
| NanoFlu | Influenza, Human | Phase 3 · NCT04120194 | Completed |
| SARS-CoV-2 rS Nanoparticle Vaccine NVX-CoV2373 | COVID-19 | Phase 3 · NCT05463068 | Completed |
| NVX-CoV2515 | COVID-19 | Phase 3 · NCT05372588 | Completed |
Also used in these trials (approved or third-party drugs, not NVAX's own candidates): Saponin-based Adjuvant, Adjuvant, SARS-CoV-2 rS antigen/Matrix-M Adjuvant, Dose 1 of Aluminum Adjuvant, Dose 2 of Aluminum Adjuvant, Dose 3 of Aluminum Adjuvant, Dose 4 of Aluminum Adjuvant, Adjuvant 1, Matrix-M Adjuvant, Monovalent Avian Influenza VLP (H5N1); Adjuvant.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
NVAX holds $622.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $83.5M/quarter from operations, an estimated runway of 22.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 8 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NVAX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Himanshu H. Shah | 5%+ holder (13D) | 10,656,964 | 6.46% | 2026-10-16 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 8,827,707 | 5.35% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 8,305,681 | 5.03% | 2026-03-31 |
| John C Jacobs President and CEO, Director · +1.77M options |
Insider | 225,680 | 0.14% | 2026-03-03 |
| Elaine O'Hara EVP, Chief Strategy Officer · +625,666 options |
Insider | 134,642 | 0.08% | 2026-03-03 |
| James Patrick Kelly EVP, CFO and Treasurer · +662,499 options |
Insider | 130,599 | 0.08% | 2026-03-07 |
| Mark J Casey EVP, Chief Legal Officer · +454,899 options |
Insider | 90,067 | 0.05% | 2026-03-03 |
| David M Mott Director · +49,596 options |
Insider | 79,770 | 0.05% | 2026-06-18 |
| Richard Douglas Director · +49,596 options |
Insider | 73,220 | 0.04% | 2026-06-18 |
| Gregg H Alton Director · +49,596 options |
Insider | 47,685 | 0.03% | 2026-06-18 |
| Richard J Rodgers Director · +49,596 options |
Insider | 47,370 | 0.03% | 2026-06-18 |
| Margaret G Mcglynn Director · +49,596 options |
Insider | 44,468 | 0.03% | 2026-06-18 |
Share count 165,009,009 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NVAX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →